Real Messenger Corporation shares rise 18.06% intraday after BioNTech's acquisition of CureVac and resolution of patent disputes.

Real Messenger Corporation rose 18.06% intraday. The company's stock price increased following the announcement of BioNTech's acquisition of CureVac, which is expected to bring transformative mRNA-based treatments to patients globally. Additionally, the resolution of patent litigation with Pfizer/BioNTech and the receipt of Clinical Trial Application (CTA) clearance from the European Medicines Agency are positive developments that may have contributed to the stock's upward movement.